Literature DB >> 14704840

Recurrent rectal cancer within the pelvis. A multicenter analysis of 123 patients and recommendations for adjuvant radiotherapy.

Stefan Höcht1, Riad Hammad, Hans-Joachim Thiel, Thomas Wiegel, Alessandra Siegmann, Jochen Willner, Peter Wust, Thomas Herrmann, Michael Eble, Michael Flentje, Detlef Carstens, Dirk Bottke, Patrick Neumann, Wolfgang Hinkelbein.   

Abstract

BACKGROUND AND
PURPOSE: Recommendations for radiation ports in adjuvant radiation therapy for rectal cancer are mainly based on analysis of recurrence patterns. To evaluate whether changes in surgical technique have influenced this pattern of recurrence, a multicenter retrospective analysis was carried out on a patient population treated recently. PATIENTS AND METHODS: 123 patients were evaluated with the help of a CT-based self-developed 3-D data file system and an extensive questionnaire. Major inclusion criteria (one sufficient) for eligibility were: histological confirmation, clear bone destruction, and a positive PET scan, or at least three minor criteria: progressive soft tissue mass, invasion of adjacent organs on follow-up CT or MRI, rising tumor markers, and typical appearance in cross-sectional imaging. Clinical or serologic signs of inflammation were exclusion criteria.
RESULTS: Initially, 54% of the evaluated patients were N0; in the remainder, N1 and N2 were distributed evenly. Initial T-category was T1 in 2%, T2 in 24%, T3 in 60%, and T4 in 13%, the male-to-female ratio was 2:1. Recurrent tumors were mainly situated in the posterior part of the bony pelvis as displayed in the figures. When abdominoperineal resection was compared to low anterior resection as primary operation, there was a significant difference in extension of recurrent tumors in the inferior parts of the pelvis (p<0.025 in all statistical tests applied), whereas no significant difference was found in the superior parts of the pelvis.
CONCLUSION: Based on these results, a modest field size reduction in adjuvant radiotherapy for rectal cancer seems feasible, offering the perspective of a reduction in acute and late side effects.

Entities:  

Mesh:

Year:  2004        PMID: 14704840     DOI: 10.1007/s00066-004-1130-8

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  3 in total

1.  Three-dimensional conformal radiotherapy combined with FOLFOX4 chemotherapy for unresectable recurrent rectal cancer.

Authors:  Jian-Bin Hu; Xiao-Nan Sun; Qi-Chu Yang; Jing Xu; Qi Wang; Chao He
Journal:  World J Gastroenterol       Date:  2006-04-28       Impact factor: 5.742

2.  Radiosensitivity of human colon cancer cell enhanced by immunoliposomal docetaxel.

Authors:  Qing-Wei Wang; Hui-Lan Lu; Chang-Cheng Song; Hong Liu; Cong-Gao Xu
Journal:  World J Gastroenterol       Date:  2005-07-14       Impact factor: 5.742

3.  Cooperative effect of BI-69A11 and celecoxib enhances radiosensitization by modulating DNA damage repair in colon carcinoma.

Authors:  Ipsita Pal; Kaushik Kumar Dey; Madhuri Chaurasia; Sheetal Parida; Subhayan Das; Y Rajesh; Kulbhushan Sharma; Tamohan Chowdhury; Mahitosh Mandal
Journal:  Tumour Biol       Date:  2015-12-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.